These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21615826)

  • 1. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma.
    Liu QW; Fu JH; Luo KJ; Yang HX; Wang JY; Hu Y; Yang H; Bella E
    Dis Esophagus; 2011 Jul; 24(5):374-80. PubMed ID: 21615826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of exon 19 and 21 mutations of EGFR gene in Chinese patients with esophageal squamous cell carcinoma.
    Cui Y; Chang D; Liu M; Lin C; Zhao B; Zhang X; Gong M
    World J Surg Oncol; 2013 Oct; 11():266. PubMed ID: 24103528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
    Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
    BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
    Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.
    Shigaki H; Baba Y; Watanabe M; Miyake K; Murata A; Iwagami S; Ishimoto T; Iwatsuki M; Yoshida N; Baba H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S485-91. PubMed ID: 23274581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
    Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
    Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
    Wang Z; Wu YL; Zhang GC; Zhou Q; Xu CR; Guo AL
    Onkologie; 2008 Apr; 31(4):174-8. PubMed ID: 18418018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
    Bircan S; Baloglu H; Kucukodaci Z; Bircan A
    Med Oncol; 2014 Aug; 31(8):87. PubMed ID: 24973952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma.
    Cui Y; Dong C; Wu BQ; Duan XC; Shi G; Gong M; Wang TY
    J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C44-8. PubMed ID: 26323923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
    Hou J; Jiang D; Zhang J; Gavine PR; Xu S; Liu Y; Xu C; Huang J; Tan Y; Wang H; Lu Y; Zheng L; Hou Y; Tan L
    Hum Pathol; 2014 Feb; 45(2):352-8. PubMed ID: 24360885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Detection and Analysis of EGFR and KRAS Mutations 
in the Patients with Lung Squamous Cell Carcinomas].
    Zhang H; Yang X; Qin N; Li X; Yang H; Nong J; Lv J; Wu Y; Zhang Q; Zhang X; Wang J; Su D; Zhang S
    Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):621-5. PubMed ID: 26483334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.
    Tsao AS; Tang XM; Sabloff B; Xiao L; Shigematsu H; Roth J; Spitz M; Hong WK; Gazdar A; Wistuba I
    J Thorac Oncol; 2006 Mar; 1(3):231-9. PubMed ID: 17409862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
    Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
    Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.
    Zhang L; Wang Y; Bai G; Zhang J; Yang M; Ma X
    Tumour Biol; 2015 Dec; 36(12):9277-83. PubMed ID: 26099724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.
    Chang YT; Chang MC; Huang KW; Tung CC; Hsu C; Wong JM
    J Gastroenterol Hepatol; 2014 May; 29(5):1119-25. PubMed ID: 24372748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mutation status of epidermal growth factor receptor and KRAS gene in non-small cell lung cancers at Xuanwei regions of Yunnan Province].
    Yang CS; Pan XY; Feng Q; Wang YY; Xu WM; Jiang T; Wang L; Yang JL; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):226-30. PubMed ID: 27033384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.